Healthcare providers and laboratories pay for oncology diagnostics that fit into existing clinical workflows, and Waiv is positioning itself to remove a persistent pain point: turning advanced AI models into clinically validated, interoperable tests that can be deployed at scale.
Paris-based Waiv has announced a $33 million (about EUR 30.56 million) financing round. The round was co-led by OTB Ventures and Alpha Intelligence Capital (AIC), with participation from Serena Data Ventures, Karista, and SistaFund.
The funding also formalises a structural shift in the market. Waiv is spinning out from Owkin, where it previously operated as Owkin Dx, moving from an internal business line to an independent platform built around clinical-grade AI testing.
Why this round fits the broader market trend
AI in diagnostics has been crowded for years, but capital is concentrating around teams that can prove two things: (1) clinical validation and (2) repeatable distribution through labs, hospitals, and pharma partners.
Waiv is leaning into that “translation to deployment” thesis. The company says its technology is clinically validated through an end-to-end AI platform that combines proprietary models, multimodal analytics, and clinical-grade tests. It also leverages the PortrAIt consortium, a multi-institutional initiative providing high-quality datasets aimed at clinical translation.
From an execution standpoint, the more important signal is commercial. AIC investor Arnaud Barthélémy points to Waiv’s “proven clinical impact” across applications such as outcome prediction and biomarker detection, framing the platform as ready for clinical settings. He also states the company has “strong revenue-generating partnerships with global pharma.” In this category, existing revenue-linked pharma relationships can materially shorten the path from product validation to scaled adoption.
Strategic lens: distribution and switching costs matter more than model quality
In precision oncology diagnostics, the defensibility is rarely the model alone. It is the ability to embed tests inside real-world workflows, with the operational plumbing to make results usable and reimbursable.
Waiv’s stated direction addresses that. Multiple sources highlight that its pharmaceutical collaborations are a differentiator, and that its technology is already used in solutions including RlapsRisk BC, MSIntuit Suite, and BRCAura. Those kinds of deployed solutions can create practical switching costs: once a lab and its clinical stakeholders trust a test’s performance, reporting format, and integration with existing processes, replacing it is slower and riskier than swapping a standalone software tool.
Interoperability is another lever. Waiv positions its approach as enabling scalable, interoperable diagnostics via platforms such as Destra, with the goal of making tests accessible within existing workflows. For buyers, that translates into fewer IT hurdles and faster time-to-value, which tends to support retention and expansion across additional indications.
What the capital is expected to fund
Waiv says the funding will:
- Deepen pharmaceutical integrations across R&D pipelines and strengthen pharma partnerships.
- Accelerate global deployment of its AI precision testing platform.
- Expand the portfolio of clinical-grade multimodal tests.
- Broaden international market access to more laboratories and healthcare providers.
Operationally, these priorities imply a scaling plan that is distribution-heavy: more integrations, more tests that can be sold through existing channels, and more geographies where lab networks and healthcare providers can adopt without bespoke implementation.
Competitive context
The AI diagnostics landscape includes both platform players and single-test companies, with incumbents in pathology and diagnostics workflows holding valuable channel access. Waiv’s angle is to combine clinically validated multimodal AI with a deployment model that is already tied into pharma and is designed to be interoperable for labs and providers.
The spin-out from Owkin is also noteworthy. It can sharpen focus, clarify product and commercial ownership, and make partnerships easier to structure, while keeping a lineage that signals credibility in data, clinical collaborations, and enterprise-grade development.
What this enables
- Faster rollout of AI-driven oncology tests across more labs and provider settings
- Deeper embedding into pharma R&D workflows, supporting repeatable enterprise integrations
- A broader test menu, which can increase account expansion potential per lab network
What to watch
- Evidence of scaled deployments beyond early adopters, including repeatability across sites
- Pace of new clinical-grade test launches and their uptake in routine workflows
- How Waiv structures and maintains pharma partnerships as it expands globally
- Regulatory and validation milestones that turn pilots into standard-of-care usage